Medicure Inc. (OTCMKTS:MCUJF) Shares Shorted: Short Interest Up 396.1% in October

Medicure Inc. (OTCMKTS:MCUJF) was the recipient of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 16,610 shares, a growth of 396.1% from the October 15th total of 3,348 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 29,975 shares, the short-interest ratio is currently 0.6 days.

Medicure Trading Up 1.1%

MCUJF traded up $0.03 during trading on Wednesday, hitting $2.64. The company’s stock had a trading volume of 5,480 shares, compared to its average volume of 12,584. Medicure has a twelve month low of $0.67 and a twelve month high of $3.45. The stock has a market cap of $27.72 million, a PE ratio of -5.18 and a beta of 1.10. The firm’s 50 day moving average price is $2.36 and its 200-day moving average price is $1.22. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.97 and a quick ratio of 0.64.

Medicure (OTCMKTS:MCUJF) last issued its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Medicure had a negative return on equity of 54.55% and a negative net margin of 23.14%. The firm had revenue of $5.36 million during the quarter, compared to analysts’ expectations of $2.45 million.

About Medicure

Medicure Inc. is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations. Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.